Press Releases/ News
Rainbow Genomics Featured in a Precision Medicine Case Study Published by Invest Hong Kong
HONG KONG, February 14, 2024
U.S. and Hong Kong-based Rainbow Genomics was featured in a Case Study “Unlocking Business Potential in Hong Kong’s Healthcare Sector” published by Invest Hong Kong, a Hong Kong Special Administrative Region (HKSAR) Government Department, responsible for Foreign Direct Investment with strategic importance to the economic development of Hong Kong.
The article describes Rainbow Genomics efforts in leveraging the city’s world-class healthcare industry to innovate faster, better and more personalized solutions.
Mr. Siu, CEO of Rainbow Genomics, said in the article: “With a critical mass and a value chain established in genomics, proteomics, artificial intelligence (AI), bioinformatics and new treatment methods, we expect Hong Kong to become an innovative hub, delivering personalized medicine for Asians and also contributing to worldwide scientific progress in the healthcare landscape.”
Read more about the article:
This Week’s South China Morning Post Features Rainbow Genomics, BlueSky Precision Medicine, And Early Detection of Autism Spectrum Disorder Leading to Early Treatment and Improved Clinical Outcome
HONG KONG, August 31, 2023
U.S. and Hong Kong-based Rainbow Genomics, and our joint-venture BlueSky Precision Medicine, were featured in today’s South China Morning Post highlighting our efforts in providing early assessment of autism spectrum disorder to middle class patients in Hong Kong. The goal is to determine autism risk in pre-symptomatic infants, toddlers and young children with a family history of autism, before symptoms appear. Early treatment, typically includes behavioral intervention without the use of medications, can be provided as soon as symptoms begin to emerge.
Compared to common clinical practice of treating 3-5 years old children already diagnosed with autism, the “early detection, early intervention” personalized medicine approach may improve treatment and clinical outcome.
The article can be found here: Hong Kong start-up aims to lower cost of early autism detection using whole genome sequencing
Web Address: https://www.scmp.com/tech/tech-trends/article/3232844/hong-kong-start-aims-lower-cost-early-autism-detection-using-whole-genome-sequencing
Article is Copyright of South China Morning Post
Rainbow Genomics Launches Retinal Dystrophy (Eye Disorders) Test Using Dual Whole-Exome and 300-Gene Deep Sequencing
Dual Sequencing Approach Determines Both Novel Variants Specific to Asian Patients, and Challenging Mutations Not Easily Detected by Routine Sequencing Methods
SAN FRANCISCO, CA, UNITED STATES, September 20, 2022 /EINPresswire.com/
Rainbow Genomics Launches Privacy-Protected Genetic Testing with the International Genetic Counseling Center
Compliance with U.S. Regulatory Guidelines and Ordering Through Rainbow's Physicians and Genetic Counselors Enable Uncompromising Patient Privacy Protection
SAN FRANCISCO, CA, UNITED STATES, September 20, 2022 /EINPresswire.com/ -- U.S. and Hong Kong-based Rainbow Genomics launches privacy-protected genetic testing with the genetic counseling team at Hong Kong-based International Genetic counseling Center. The privacy protection paradigm covers all Rainbow products, including whole genome sequencing, whole exome sequencing, cancer, cardiovascular disorder and carrier genetic tests.
Rainbow Genomics Launches Polygenic and Trait Analysis for Obesity Management Using Whole Genome Sequencing
Metabolic Disorder Genetic Analysis, Coupled with Nutrigenomic and Exercise Adaptation Trait Assessment, Enables Lifestyle Changes to Reduce Obesity
SAN FRANCISCO, CA, UNITED STATES, September 19, 2022 /EINPresswire.com/ -- U.S. and Hong Kong-based Rainbow Genomics launches a comprehensive obesity genetic analysis program, including whole genome sequencing to identify genomic variations associated with metabolic disorders, responses to food and nutrition, eating behavior and exercise adaptation.
Polygenic Risk Prediction of Heart Attack in Asians Enabled by Whole Genome Sequencing
Extensive Curation of Asian-Specific Genetic Variants Enables Identification of Individuals at Elevated Risk of a Heart Attack
SAN FRANCISCO, CA, UNITED STATES, September 14, 2022 /EINPresswire.com/ -- U.S. and Hong Kong-based Rainbow Genomics launches polygenic risk assessment for heart attack in Asian individuals using whole genome sequencing data.
Proteomic Assessment for Prediction of Four-Year Likelihood of Heart Attack
4000-Protein Surrogates with a Median Time-To-Event Prediction of 1.7 Years for High-Risk Individuals
SAN FRANCISCO, CALIFORNIA, UNITED STATES, September 8, 2022 /EINPresswire.com/ -- U.S. and Hong Kong-based Rainbow Genomics launches a proteomics-based test to assess four-year likelihood of myocardial infarction (heart attack) in both asymptomatic individuals and at-risk patients.
Whole Genome Sequencing Test Enables Diagnosis of Growth Abnormality and Sex Development Disorders in Children
Affordable First-Tier Testing for Patients Affected by Disorders of Sex Development, Growth Hormone Deficiency, Short Stature, and Early Puberty
SAN FRANCISCO, CALIFORNIA, UNITED STATES, September 8, 2022/EINPresswire.com/
Deep Clinical Assessment with Whole Genome Sequencing Enables Diagnosis of Adult Unexplained Abnormalities
Successful Genetic Assessment Reduces Misdiagnoses and Supports Early Interventions to Prevent Adult Premature Mortality
SAN FRANCISCO, CALIFORNIA, UNITED STATES, March 6, 2022 /EINPresswire.com/
Pharmacogenomic Testing Improves Psychiatric Drug Selections for Treatment-Intolerant or Treatment-Resistant Patients
Drug efficacy test results inform alternative medication selections when first-line treatment is ineffective with no guidelines for drug substitutions
SAN FRANCISCO, CALIFORNIA, UNITED STATES, December 12, 2021 /EINPresswire.com/
Rainbow Genomics Whole Genome Sequencing Test Determines Co-Occurring Conditions (Comorbidity) in Autistic Children
Establish a diagnosis by confirming spontaneous (de novo) and challenging mutations in over 1000 newly-reported genes associated with autism spectrum disorder
SAN FRANCISCO, CALIFORNIA, USA, October 19, 2021 /EINPresswire Version/
Hong Kong and U.S. based Rainbow Genomics announced today the introduction of a multi-genomic testing strategy for children affected by autistic spectrum disorder. The test is especially appropriate for children presented with co-occurring conditions, also known as comorbidity, including speech delay, intellectual disability, developmental regression, movement abnormality, and seizures.
Rainbow Genomics Launches Pan-Cancer Test to Detect Genomic Rearrangements and Genetic Disorders Associated with Cancers
Dual Large Genomic Rearrangement Sequencing and Whole Exome Sequencing Increases Diagnostic Yields for Hereditary Cancer Patients and Asymptomatic Individuals
SAN FRANCISCO, CALIFORNIA, UNITED STATES, October 3, 2021 /EINPresswire Version/
Rainbow Genomics Launches Whole Genome Sequencing Supported by Multiple Genomic Technologies
Enables Timely Diagnosis for Patients Affected by Rare Diseases, Developmental and Neurological Disorders
HONG KONG & SAN FRANCISCO, September 26, 2021 /EINPresswire Version/
Hong Kong and U.S. based Rainbow Genomics announced the integration of multiple genomic technologies and bioinformatics platforms, with primary testing based on whole genome sequencing, to push for high diagnostic yield for pediatric and adult patients affected by rare diseases, developmental, behavioral and neurological disorders.
Rainbow Genomics Launches Whole Genome Sequencing Tests at Low Price Points Comparable to Exome Sequencing and Panel Testing
San Francisco, November 6, 2020
Whole Genome Analysis Increases Success in Finding a Genetic Cause Associated with Pediatric and Adult Disorders
Fast Testing Results
Rainbow Genomics Launches Rapid Trio Whole Genome Sequencing for Pregnancy Cases with Prenatal Ultrasound Abnormalities
High diagnostic yield delivered by trio whole genome sequencing coupled with a one-week turnaround time provides physicians with a timely diagnosis.
San Francisco, March 9, 2020
Rainbow Genomics Launches Rapid Whole Genome Sequencing Test for Newborns with Complex Clinical Symptoms
The one-week turnaround time coupled with rapid analysis and clinical interpretation helps diagnose critically-ill newborns.
San Francisco, March 9, 2020
Rainbow Genomics to Sponsor Exome and Pharmacogenomic Seminars at the Hong Kong Society of Medical Genetics 19th Annual General Meeting cum Scientific Meeting
Seminar: “Clinical Whole Exome Sequencing and Pharmacogenomic Testing for Patients and Healthy Individuals - U.S. & Hong Kong Clinical Perspective”
Speakers:
Wayne W. Grody, M.D., Ph.D. Director, Divisions of Medical Genetics and Molecular Diagnostics, UCLA School of Medicine, Los Angeles, California
Stephen Lam, M.D. Director of Clinical Genetics Service, Hong Kong Sanatorium and Hospital
Venue: Power A Space, 4/F Tung Hip Commercial Building, 244-248 Des Voeux Road Central, Central, Hong Kong 香港德輔道中244-248號, 東協商業大廈4樓 (Sheung Wan MTR Exit A1)
Date: 18 December 2018
Time: 6:30-8:30 pm (Reception at 6:00 pm)
Come join us at the HKSMG meeting
San Francisco, November 24, 2018 (Rainbow News Release)
Rainbow Genomics to Present at the Upcoming 68th Annual Meeting of the American Society of Human Genetics
Title: “Mutation spectrum identified by germline testing of hereditary cancers from 500 healthy Chinese individuals using an accessible 30-gene panel following ACMG guidelines”
Date/Location: Tuesday, October 16 - Saturday, October 20, 2018, at the San Diego Convention Center (Room 22) in San Diego, California.
Come join us at the ASHG meeting
San Francisco, October 3, 2018 (Rainbow News Release)
Rainbow Genomics, joining 16 other countries, contributes to Color’s “Genetic Insights into Hereditary Cancer Risk in the Global Population”.
The presentation was given at the 42nd Annual Scientific Meeting of the Human Genetics Society of Australasia.
7952 international hereditary cancer high risk individuals from 17 countries (Argentina, Australia, Belgium, Brazil, Canada, Colombia, Spain, Finland, United Kingdom, Greece, Hong Kong, Ireland, Israel, Japan, Mexico, Peru, Uruguay) received the physician ordered 30-gene or 19-gene Color hereditary cancer test to assess their risk for hereditary cancer. These tests cover breast cancer as well as ovarian, colorectal, melanoma, pancreatic, prostate, uterine and stomach cancers.
Globally, the pathogenic mutation rate was 15.6%.
San Francisco, September 17, 2018 (Rainbow News Release)
Rainbow Genomics and Color Genomics Team Up to Provide Access to Affordable Hereditary Cancer and Heart Health Genetic Risk Assessment Tests in Asia
Partnership combines local support with global capabilities to deliver affordable tests to identify genetic mutations associated with an increased risk for hereditary cancer and inherited heart conditions for which early knowledge can make a difference.
San Francisco, May 23, 2018 (Newswire)
Rainbow Genomics Announces the Integration of Clinical Interpretation Services from the UCLA Clinical Genomics Center Supporting Whole Exome Sequencing Tests
The fully-integrated capabilities deliver whole exome sequencing tests covering cardio, adult and pediatric genetic disorders. Clinical reports based on clear medical evidence will be issued by U.S. board-certified medical directors at the UCLA Clinical Genomics Center.
San Francisco, April 26, 2018 (PRWEB)
Baylor Genetics Partners With Rainbow Genomics Offering Adult Wellness Screening and High-Risk Cancer Exome Sequencing Tests in Asian Pacific
Product offering includes adult exome screening, high-risk cancer and wellness cancer tests.
September 25, 2017 (Newswire.com)
OneOme and Rainbow Genomics Team Up to Provide Innovative Genomic Services to Patients in Hong Kong, Japan, and Macau
PARTNERSHIP COMBINES EXOME SEQUENCING, PHARMACOGENOMICS EXPERTISE.
September 13, 2017